Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SANA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0905 : 49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SANASana Biotechnology Inc
2024/05/0905 : 21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
2024/05/0905 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2024/05/0905 : 05GlobeNewswire Inc.Sana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
2024/05/0705 : 05GlobeNewswire Inc.Sana Biotechnology to Present at May and June 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
2024/03/0906 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
2024/03/0906 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
2024/03/0106 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2024/03/0106 : 05GlobeNewswire Inc.Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
2024/02/2906 : 05GlobeNewswire Inc.Sana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:SANASana Biotechnology Inc
2024/02/1506 : 00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
2024/02/1406 : 05GlobeNewswire Inc.Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHPNASDAQ:SANASana Biotechnology Inc
2024/02/1306 : 05GlobeNewswire Inc.Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:SANASana Biotechnology Inc
2024/02/0907 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2024/02/0906 : 49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SANASana Biotechnology Inc
2024/02/0815 : 22GlobeNewswire Inc.Sana Biotechnology Announces Pricing of Upsized Public OfferingNASDAQ:SANASana Biotechnology Inc
2024/02/0811 : 59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:SANASana Biotechnology Inc
2024/02/0807 : 05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SANASana Biotechnology Inc
2024/02/0806 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2024/02/0806 : 01GlobeNewswire Inc.Sana Biotechnology Announces Proposed Public Offering of Common StockNASDAQ:SANASana Biotechnology Inc
2024/01/0923 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2024/01/0523 : 00GlobeNewswire Inc.Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell MalignanciesNASDAQ:SANASana Biotechnology Inc
2024/01/0406 : 05GlobeNewswire Inc.Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
2023/12/1906 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
2023/12/1606 : 34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
2023/12/1206 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
2023/12/1123 : 00GlobeNewswire Inc.Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual MeetingNASDAQ:SANASana Biotechnology Inc
2023/12/0206 : 05GlobeNewswire Inc.Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune SystemNASDAQ:SANASana Biotechnology Inc
2023/11/2809 : 01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:SANASana Biotechnology Inc
2023/11/2123 : 00GlobeNewswire Inc.Sana Biotechnology to Present at November and December 2023 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA

最近閲覧した銘柄

Delayed Upgrade Clock